Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.23 USD | +2.43% | -6.02% | +446.60% |
May. 30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
May. 30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+446.60% | 239M | |
+46.19% | 55.7B | |
+39.58% | 39.91B | |
-6.14% | 39.57B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
+28.38% | 12.17B | |
+24.18% | 12.12B | |
-0.35% | 12.12B |
- Stock Market
- Equities
- CADL Stock
- News Candel Therapeutics, Inc.
- UBS Adjusts Candel Therapeutics Price Target to $8 From $11, Maintains Buy Rating